Spaulding Clinical Research, a US-based provider of clinical pharmacology and cardiac core laboratory services, has announced a transatlantic partnership with France’s Eurofins Optimed Clinical Research to support global studies by pharmaceutical and biotechnology companies.
The tie-up will leverage both companies’ strengths and facilitate collaboration on integrated clinical services “to engage pharmaceutical clients who demand a global footprint”, the new partners said.
The joint offering ranges from study design and execution/conduct to data management, statistical analysis and medical writing. Eurofins Optimed’s portfolio encompasses Phase I- IV clinical research services, including clinical pharmacology units in Grenoble and Lyon, France.
The company’s chief executive officer and president, Dr Yves Donazzolo, singled out Spaulding Clinical’s achievement of ISO (international standards) certification, which “is not common among US clinical research facilities”.
Spaulding’s “innovative” systems approach to electronic data capture [EDC] is also “something that we have been looking to implement, so the partnership will allow us to consider how to collaborate more closely as these systems are put in place”, Donazzolo added.
The US company’s clinical pharmacology unit in West Bend, Wisconsin is paperless, with a Phase I EDC system and bi-directional interfaces to safety laboratory and telemetry systems.
Daniel Selness, general manager and senior vice president of operations for Spaulding Clinical, cited Eurofins Optimed’s “culture of excellence and research facilities designed to execute high-quality studies”, which were “very impressive to our team”.